| HOME >> BIOLOGY >> TECHNOLOGY |
MOUNTAIN VIEW, Calif., Oct. 7 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that data on QNEXA®, an investigational drug candidate, are highlighted in six poster presentations at the 28th Annual Scientific Meeting of The Obesity Society, being held October 8-12, 2010 in San Diego, California.
Following are details about the poster presentations:
The Obesity Society 28th Annual Scientific Meeting at The San Diego Convention Center in San Diego, CA
All six posters will be presented in Poster Session #2 (Hall H) on Sunday, October 10, 2010 from 9:30 am to 1:45 pm and from 3:15 pm to 6:30 pm.
Presenters will be at their posters from 12:30 pm to 1:30 pm. Presenter:
Wesley W. Day, PhDAuthors:
Day, Najarian, Troupin, Tam, PetersonTitle:
Low-Dose, Controlled-Release Phentermine/Topiramate Reduces Hunger and Increases Satiety, Leading to Weight Loss in Overweight/Obese Adults (Abstract # 212898; Poster # 490-P)Presenter:
Kishore M. Gadde, MDAuthors:
Gadde, Peterson, DayTitle:
Clinically Meaningful Weight-Loss Outcomes With Low-Dose, Controlled-Release Phentermine/Topiramate in Overweight/Obese Subjects (Abstract # 212885; Poster #486-P)Presenter:
Dympna Gallagher, EdDAuthors:
Gallagher, Punyanitya, Bowden, PetersonTitle:
Low-Dose, Controlled-Release Phentermine/Topiramate Reduces Adiposity, Improves Cardiometabolic Risk in Overweight/Obese Patients (Abstract # 212891; Poster # 488-P)Presenter:
W. Timothy Garvey, MDAuthors:
Garvey, Peterson, Troupin, BowdenTitle:
Low-Dose, Controlled-Release Phentermine/Topiramate for Weight Loss and Management of Type 2 Diabetes Mellitus (Abstract # 212889; Poster # 492-P)Presenter:
Samuel Klein, MDAuthors:
Klein, Najarian, DayTitle:
Weight Loss With Once-Daily, Low-Dose, Controlled-Rele
'/>"/>
| SOURCE VIVUS, Inc. Copyright©2010 PR Newswire. All rights reserved |